The present invention relates to a compound of formula (I-0) or a salt thereof. The invention further relates to the use of such compound as a colouring agent. The invention also relates to a colouring composition comprising such compound.

An aqueous dye dispersion for an aqueous ink including a dye derivative as indicated at Formula (1) below; a water-insoluble dye; a dispersant; and water, makes it possible to provide an aqueous dye dispersion for aqueous ink, which reduces flocculation of particles within aqueous ink even when the aqueous ink is prepared, and has satisfactory dispersion stability during storage, thereby providing an aqueous ink having satisfactory dispersion stability during storage. ##STR00001##

An aqueous dye dispersion for an aqueous ink including a dye derivative as indicated at Formula (1) below; a water-insoluble dye; a dispersant; and water, makes it possible to provide an aqueous dye dispersion for aqueous ink, which reduces flocculation of particles within aqueous ink even when the aqueous ink is prepared, and has satisfactory dispersion stability during storage, thereby providing an aqueous ink having satisfactory dispersion stability during storage. ##STR00001##

An aqueous dye dispersion for an aqueous ink including a dye derivative as indicated at Formula (1) below; a water-insoluble dye; a dispersant; and water, makes it possible to provide an aqueous dye dispersion for aqueous ink, which reduces flocculation of particles within aqueous ink even when the aqueous ink is prepared, and has satisfactory dispersion stability during storage, thereby providing an aqueous ink having satisfactory dispersion stability during storage.

##STR00001##

(At Formula (1), R.sup.1 is a group as indicated at Formula (2), below, and R.sup.2 is a group as indicated at Formula (3), below. m and n are each 0 or 1 but m+n=1. R.sup.3 is at least one species selected from among a hydroxyl group and an amino group. l is 0 to 2; when l=2, R.sup.3 may respectively be the same or different.)

##STR00002##

(At Formula (3), R.sup.4 is a phenylene group or an alkylene group having 1 to 4 carbons; R.sup.5 and R.sup.6 are independently selected alkyl groups having 1 to 4 carbons.)

There is disclosed a compound, a pharmaceutical composition and a method of treatment using a pharmaceutical composition comprising a tethering moiety that is capable of binding to a macrophage migration inhibitory factor (MIF) polypeptide, optionally linked to a linker moiety and further covalently bound to a drug moiety or imaging agent. More specifically, there is disclosed a genus of affinity-tethering moieties covalently bound to a drug moiety or imaging agent either directly or optionally via a linker moiety to covalently link the tethering moiety to a drug moiety. Without being bound by theory, the disclosed pharmaceutical compounds are targeted to cancer cells or immune cells via an affinity-tethering moiety that hitch-hikes to or into its target cell while bound to endogenous MIF.